ZALEVSKY JONATHAN (Chief R&D Officer) sold 9.0% of their position (1.72K shares) of NEKTAR THERAPEUTICS on the open market
Open‑market sale worth $57.7K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 9/8/2025ACC: 0000950170-25-113692
Officer· Chief R&D Officer
Since Oct 2019
-1.72K
Net shares
Net seller
$57.7K
Total sold
4
Open market trades
0B · 4S
4
Total transactions
1.72K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−793.00
Price / share
$32.43
Trade value
$25.72K
% of position
4.1%
9/4/2025
19.18K→18.39K
Common Stock
Direct
Shares
−432.00
Price / share
$33.60
Trade value
$14.52K
% of position
2.3%
9/4/2025
18.39K→17.96K
Common Stock
Direct
Shares
−189.00
Price / share
$34.41
Trade value
$6.50K
% of position
1.1%
9/4/2025
17.96K→17.77K
Common Stock
Direct
Shares
−307.00
Price / share
$35.69
Trade value
$10.96K
% of position
1.7%
9/4/2025
17.77K→17.46K
Total
Net shares
−1.72K
Net value
-$57.69K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/4/2025 | S · Sale | −793.00 | $32.43 | $25.72K | 4.1% | 19.18K | 18.39K |
| Common Stock Direct | 9/4/2025 | S · Sale | −432.00 | $33.60 | $14.52K | 2.3% | 18.39K | 17.96K |
| Common Stock Direct | 9/4/2025 | S · Sale | −189.00 | $34.41 | $6.50K | 1.1% | 17.96K | 17.77K |
| Common Stock Direct | 9/4/2025 | S · Sale | −307.00 | $35.69 | $10.96K | 1.7% | 17.77K | 17.46K |
| Total | −1.72K | -$57.69K | ||||||
Derivative Transactions0
No derivative transactions reported